Q-omics provides the consensus-scored CDRT15P3 profile across patient tissues and cancer cell-line models. CDRT15P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CDRT15P3 is differentially expressed in 6, with the highest sampling consensus in PAAD. Additionally, CDRT15P3 RNA expression shows 6,138 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, PAAD, and STAD as cancer lineages where CDRT15P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDRT15P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDRT15P3 survival associations across molecular data types. CDRT15P3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDRT15P3 RNA expression–survival associations across cancer types. High CDRT15P3 expression shows unfavorable associations in UVM, READ, MESO and COAD, but favorable associations in OV and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CDRT15P3 RNA expression.
This table summarizes CDRT15P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CDRT15P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDRT15P3 shows lower tumor expression in PAAD and STAD and higher tumor expression in LUSC, PRAD, THCA and LUAD. The PAAD box plot shows higher CDRT15P3 RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p = .037).
This table shows molecular features associated with CDRT15P3 in patient tissues and cancer cell lines. In patient samples, CDRT15P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CDRT15P3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
